Ameritas Investment Partners’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Ameritas Investment Partners’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,048	Closed	-$122K	–	3306
2023 Q1	$122K	Hold	5,048	–	–	﹤0.01%	1414
2022 Q4	$45K	Buy	5,048 +1,304	+35%	+$10.5K	﹤0.01%	2132
2022 Q3	$16K	Hold	3,744	–	–	﹤0.01%	2638
2022 Q2	$14K	Hold	3,744	–	–	﹤0.01%	2733
2022 Q1	$27K	Hold	3,744	–	–	﹤0.01%	2434
2021 Q4	$21K	Hold	3,744	–	–	﹤0.01%	2634
2021 Q3	$24K	Hold	3,744	–	–	﹤0.01%	2614
2021 Q2	$32K	Hold	3,744	–	–	﹤0.01%	2472
2021 Q1	$39K	Hold	3,744	–	–	﹤0.01%	2235
2020 Q4	$63K	Hold	3,744	–	–	﹤0.01%	1849
2020 Q3	$48K	Hold	3,744	–	–	﹤0.01%	1866
2020 Q2	$53K	Buy	+3,744	New	+$47.3K	﹤0.01%	1792

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Ameritas Investment Partners's PRVB Position: Q2 2023 in Review

Ameritas Investment Partners sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 5,048 shares — an estimated $122K sold.

Ameritas Investment Partners first reported a position in PRVB in Q2 2020 and held it in 12 quarters. The position peaked at $122K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Ameritas Investment Partners reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Ameritas Investment Partners sold 5,048 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $122K.
Ameritas Investment Partners first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
Ameritas Investment Partners's Provention Bio, Inc. Common Stock position peaked at $122K in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Ameritas Investment Partners's 13F filing for Q2 2023, filed 11 Aug 2023.